ArticlePediatric radiology2026
Multi-pool chemical exchange saturation transfer magnetic resonance imaging as a molecular-specific biomarker: detecting histopathological changes in neonatal hypoxic-ischemic encephalopathy.
Article in Pediatric radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNeonatal hypoxic-ischemic encephalopathy (HIE) diagnosis is confounded by heterogeneous neural injury and metabolic dysfunction. Multi-pool chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) uniquely quantifies amide proton transfer, nuclear Overhauser enhancement, and magnetization transfer signals, providing multi-parametric assessment of HIE pathophysiology.
objectiveTo investigate whether multi-pool CEST MRI can serve as a molecular-specific biomarker for histopathological alterations in HIE and assess its efficacy in grading disease severity. MATERIALS AND
methodsThis prospective study included 20 neonates with HIE and 42 age-matched controls undergoing 3.0-T CEST MRI. Imaging data were spatially normalized to a neonatal atlas for region-specific analysis (caudate, putamen, thalamus, pallidum, amygdala, hippocampus). Group differences in CEST signals (amide proton transfer, nuclear Overhauser enhancement, magnetization transfer) were analyzed via Wilcoxon tests, with diagnostic performance evaluated through receiver operating characteristic analysis.
resultsCompared to controls, HIE neonates showed significant reductions in amide proton transfer (bilateral putamen, right hippocampus/pallidum/amygdala, left thalamus/caudate), nuclear Overhauser enhancement (left thalamus/caudate/putamen), and magnetization transfer signals (bilateral thalamus/pallidum/putamen, left caudate; all P<0.05). Subgroup analysis revealed progressive metabolic decline: moderate-to-severe HIE exhibited further amide proton transfer reduction in the right thalamus, nuclear Overhauser enhancement decreases in bilateral hippocampus, and magnetization transfer decreases in left hippocampus/thalamus compared to mild cases (all P<0.05). Notably, conventional amide proton transfer-weighted imaging showed no significant changes, as the reduction in amide proton transfer signal was offset by a concurrent decrease in the nuclear Overhauser enhancement, highlighting the superiority of multi-pool analysis. Left hippocampal nuclear Overhauser enhancement demonstrated exceptional severity discrimination (area under curve (AUC)=0.96), while a multi-region integrated model achieved perfect staging accuracy (AUC=1.00).
conclusionMulti-pool CEST MRI effectively captures histopathological changes in neonatal HIE, with left hippocampal nuclear Overhauser enhancement emerging as a precise biomarker for severity stratification. The combined dynamics of amide proton transfer, nuclear Overhauser enhancement, and magnetization transfer signals provide noninvasive insights into metabolic-pathological correlations, highlighting its transformative potential for early diagnosis and targeted therapeutic monitoring.
Indexed as
Identifiers
41123647What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.